3-10-2019 jacob plieth vantage

US approves immunotherapy for breast cancer for first time

Sharon Begley | 
Roche’s cancer immunotherapy Tecentriq (atezolizumab), a PD-L1 inhibitor, scored its fifth Food and Drug Administration approval on [March 8], for advanced triple-negative ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists